|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2017
gptkb:FDA
|
|
gptkbp:atccode
|
J05 AP53
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:brand
|
gptkb:Mavyret
|
|
gptkbp:can_be_combined_with
|
gptkb:glecaprevir
|
|
gptkbp:chemical_formula
|
C22 H26 N4 O4 S
|
|
gptkbp:class
|
antiviral
|
|
gptkbp:clinical_trial
|
Phase 3 trials
chronic hepatitis C
|
|
gptkbp:clinical_use
|
in combination with other antiviral agents
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:dosage_form
|
300 mg once daily
|
|
gptkbp:duration
|
8 to 12 weeks
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pibrentasvir
|
|
gptkbp:interacts_with
|
gptkb:St._John's_Wort
gptkb:carbamazepine
gptkb:rifampin
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_effective_against
|
over 95% cure rate
|
|
gptkbp:lifespan
|
5 to 10 hours
|
|
gptkbp:marketed_as
|
gptkb:Mavyret
|
|
gptkbp:mechanism_of_action
|
NS5 A inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:patient_population
|
adults and children over 12 years
|
|
gptkbp:research
|
ongoing studies for resistance
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
|
|
gptkbp:targets
|
gptkb:HCV_NS5_A_protein
|
|
gptkbp:used_for
|
treatment of hepatitis C
|
|
gptkbp:bfsParent
|
gptkb:virus
|
|
gptkbp:bfsLayer
|
4
|